Abstract
The formation of new blood vessels, called angiogenesis, is an essential pathophysiological process in which several families of regulators have been implicated. Among these, vascular endothelial growth factor A (VEGFA; also known as VEGF) and its two tyrosine kinase receptors, VEGFR1 and VEGFR2, represent a key signalling pathway mediating physiological angiogenesis and are also major therapeutic targets. VEGFA is a member of the gene family that includes VEGFB, VEGFC, VEGFD and placental growth factor (PLGF). Three decades after its initial isolation and cloning, VEGFA is arguably the most extensively investigated signalling system in angiogenesis. Although many mediators of angiogenesis have been identified, including members of the FGF family, angiopoietins, TGFβ and sphingosine 1-phosphate, all current FDA-approved anti-angiogenic drugs target the VEGF pathway. Anti-VEGF agents are widely used in oncology and, in combination with chemotherapy or immunotherapy, are now the standard of care in multiple malignancies. Anti-VEGF drugs have also revolutionized the treatment of neovascular eye disorders such as age-related macular degeneration and ischaemic retinal disorders. In this Review, we emphasize the molecular, structural and cellular basis of VEGFA action as well as recent findings illustrating unexpected interactions with other pathways and provocative reports on the role of VEGFA in regenerative medicine. We also discuss clinical and translational aspects of VEGFA. Given the crucial role that VEGFA plays in regulating angiogenesis in health and disease, this molecule is largely the focus of this Review.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman, J. & Klagsbrun, M. Angiogenic factors. Science 235, 442–447 (1987).
Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873–887 (2011).
Dudley, A. C. & Griffioen, A. W. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis 26, 313–347 (2023).
Paik, D. T. et al. Single-cell RNA sequencing unveils unique transcriptomic signatures of organ-specific endothelial cells. Circulation 142, 1848–1862 (2020).
Paik, D. T., Cho, S., Tian, L., Chang, H. Y. & Wu, J. C. Single-cell RNA sequencing in cardiovascular development, disease and medicine. Nat. Rev. Cardiol. 17, 457–473 (2020).
Rohlenova, K. et al. Single-cell RNA sequencing maps endothelial metabolic plasticity in pathological angiogenesis. Cell Metab. 31, 862–877.e14 (2020).
Cao, Y., Langer, R. & Ferrara, N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat. Rev. Drug Discov. 22, 476–495 (2023).
Risau, W. & Flamme, I. Vasculogenesis. Ann. Rev. Cell Dev. Biol. 11, 73–91 (1995).
Chung, A. S. & Ferrara, N. Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27, 563–584 (2011).
Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464–478 (2007).
Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581–611 (2004).
Coultas, L., Chawengsaksophak, K. & Rossant, J. Endothelial cells and VEGF in vascular development. Nature 438, 937–945 (2005).
Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17, 611–625 (2016).
Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M. G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl Acad. Sci. USA 88, 9267–9271 (1991).
Olofsson, B. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl Acad. Sci. USA 93, 2576–2581 (1996).
Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 1751 (1996).
Achen, M. G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA 95, 548–553 (1998).
Lyttle, D. J., Fraser, K. M., Flemings, S. B., Mercer, A. A. & Robinson, A. J. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68, 84–92 (1994).
Meyer, M. et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18, 363–374 (1999).
Rauniyar, K., Bokharaie, H. & Jeltsch, M. Expansion and collapse of VEGF diversity in major clades of the animal kingdom. Angiogenesis 26, 437–461 (2023).
Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851–858 (1989).
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309 (1989).
Hiratsuka, S. et al. Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Mol. Cell Biol. 25, 355–363 (2005).
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003).
Benjamin, L. E. & Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad. Sci. USA 94, 8761–8766 (1997).
Rattner, A., Wang, Y. & Nathans, J. Signaling pathways in neurovascular development. Annu. Rev. Neurosci. 45, 87–108 (2022).
Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947–11954 (1991).
Houck, K. A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806–1814 (1991).
Poltorak, Z. et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272, 7151–7158 (1997).
Ferrara, N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol. Biol. Cell 21, 687–690 (2010).
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031–26037 (1992).
Park, J. E., Keller, G. A. & Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317–1326 (1993).
Keyt, B. A. et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271, 7788–7795 (1996).
Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D. & Iruela-Arispe, M. L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169, 681–691 (2005).
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
Kunnapuu, J., Bokharaie, H. & Jeltsch, M. Proteolytic cleavages in the VEGF family: generating diversity among angiogenic VEGFs, essential for the activation of lymphangiogenic VEGFs. Biology 10, 167 (2021).
Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495–502 (1999).
Bates, D. O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123–4131 (2002).
Harper, S. J. & Bates, D. O. VEGF-A splicing: the key to anti-angiogenic therapeutics. Nat. Rev. Cancer 8, 880–887 (2008).
Woolard, J. et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822–7835 (2004).
Kikuchi, R. et al. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat. Med. 20, 1464–1471 (2014).
Kawamura, H., Li, X., Harper, S. J., Bates, D. O. & Claesson-Welsh, L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res. 68, 4683–4692 (2008).
Dardente, H., English, W. R., Valluru, M. K., Kanthou, C. & Simpson, D. Debunking the myth of the endogenous antiangiogenic Vegfaxxxb transcripts. Trends Endocrinol. Metab. 31, 398–409 (2020).
Eswarappa, S. M. et al. Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell 157, 1605–1618 (2014).
Xin, H., Zhong, C., Nudleman, E. & Ferrara, N. Evidence for pro-angiogenic functions of VEGF-Ax. Cell 167, 275–284.e6 (2016).
Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843–845 (1992).
Palazon, A., Goldrath, A. W., Nizet, V. & Johnson, R. S. HIF transcription factors, inflammation, and immunity. Immunity 41, 518–528 (2014).
Krock, B. L., Skuli, N. & Simon, M. C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2, 1117–1133 (2011).
Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604–4613 (1996).
Kelly, B. D. et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93, 1074–1081 (2003).
Kaelin, W. G. Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865–873 (2008).
Fischer, S. et al. Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am. J. Physiol. 276, C812–C820 (1999).
Irwin, D. C. et al. A potential role for reactive oxygen species and the HIF-1α-VEGF pathway in hypoxia-induced pulmonary vascular leak. Free Radic. Biol. Med. 47, 55–61 (2009).
Tang, N. et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6, 485–495 (2004).
Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005–3015 (1998).
Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131–138 (2001).
Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439–442 (1996).
Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435–439 (1996).
Dunwoodie, S. L. The role of hypoxia in development of the mammalian embryo. Dev. Cell 17, 755–773 (2009).
Vinores, S. A. et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J. Cell Physiol. 206, 749–758 (2006).
Mizukami, Y. et al. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 64, 1765–1772 (2004).
Mizukami, Y. et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J. Biol. Chem. 281, 13957–13963 (2006).
Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737–744 (2000).
Fujioka, S. et al. NF-κB and AP-1 connection: mechanism of NF-κB-dependent regulation of AP-1 activity. Mol. Cell Biol. 24, 7806–7819 (2004).
Shchors, K. et al. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β. Genes Dev. 20, 2527–2538 (2006).
Mizukami, Y. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat. Med. 11, 992–997 (2005).
Arany, Z. et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 451, 1008–1012 (2008).
Xue, Y. et al. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell Metab. 9, 99–109 (2009).
Takahashi, K. et al. Endogenous oxidative stress, but not ER stress, induces hypoxia-independent VEGF120 release through PI3K-dependent pathways in 3T3-L1 adipocytes. Obesity 21, 1625–1634 (2013).
Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling — in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359–371 (2006).
Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 8, 519–527 (1990).
Iljin, K. et al. VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15, 1028–1036 (2001).
Neufeld, G. et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 12, 13–19 (2002).
Cross, M. J., Dixelius, J., Matsumoto, T. & Claesson-Welsh, L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488–494 (2003).
de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989–991 (1992).
Jakeman, L. B., Winer, J., Bennett, G. L., Altar, C. A. & Ferrara, N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89, 244–253 (1992).
Sawano, A., Takahashi, T., Yamaguchi, S. & Shibuya, M. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCγ. Biochem. Biophys. Res. Commun. 238, 487–491 (1997).
Meyer, R. D., Mohammadi, M. & Rahimi, N. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J. Biol. Chem. 281, 867–875 (2006).
Gille, H. et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J. 19, 4064–4073 (2000).
Park, J. E., Chen, H. H., Winer, J., Houck, K. A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646–25654 (1994).
Davis-Smyth, T., Chen, H., Park, J., Presta, L. G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919–4927 (1996).
Wiesmann, C. et al. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695–704 (1997).
Christinger, H. W., Fuh, G., de Vos, A. M. & Wiesmann, C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J. Biol. Chem. 279, 10382–10388 (2004).
Markovic-Mueller, S. et al. Structure of the full-length VEGFR-1 extracellular domain in complex with VEGFA. Structure 25, 341–352 (2017).
Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9, 225–230 (2006).
Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA 90, 10705–10709 (1993).
Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).
Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683 (2004).
Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995).
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl Acad. Sci. USA 95, 9349–9354 (1998).
Murakami, M. et al. Signaling of vascular endothelial growth factor receptor- 1 tyrosine kinase promotes rheumatoid arthritis through activation of monocyte/macrophages. Blood 108, 1849–1856 (2006).
Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289–300 (2002).
Wu, Y. et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer 119, 1519–1529 (2006).
Yao, J. et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PLGF antibodies efficacy. Proc. Natl Acad. Sci. USA 108, 11590–11595 (2011).
LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890–893 (2003).
Terman, B. I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579–1586 (1992).
Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N. & Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl Acad. Sci. USA 90, 7533–7537 (1993).
Tammela, T. & Alitalo, K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460–476 (2010).
Shibuya, M. & Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549–560 (2005).
Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62–66 (1995).
Fuh, G., Li, B., Crowley, C., Cunningham, B. & Wells, J. A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197–11204 (1998).
Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T. & Ballmer-Hofer, K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat. Struct. Mol. Biol. 14, 249–250 (2007).
Takahashi, T., Ueno, H. & Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221–2230 (1999).
Gerber, H. P. et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336–30343 (1998).
Tan, W. et al. An essential role for Rac1 in endothelial cell function and vascular development. FASEB J. 22, 1829–1838 (2008).
Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. & Shibuya, M. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl Acad. Sci. USA 102, 1076–1081 (2005).
Xia, P. et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98, 2018–2026 (1996).
Takahashi, T., Yamaguchi, S., Chida, K. & Shibuya, M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768–2778 (2001).
Ji, Q. S. et al. Essential role of the tyrosine kinase substrate phospholipase C-γ1 in mammalian growth and development. Proc. Natl Acad. Sci. USA 94, 2999–3003 (1997).
Jekely, G., Sung, H. H., Luque, C. M. & Rorth, P. Regulators of endocytosis maintain localized receptor tyrosine kinase signaling in guided migration. Dev. Cell 9, 197–207 (2005).
Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C. & Dejana, E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174, 593–604 (2006).
Ballmer-Hofer, K., Andersson, A. E., Ratcliffe, L. E. & Berger, P. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 118, 816–826 (2011).
Nakayama, M. et al. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat. Cell Biol. 15, 249–260 (2013).
Sawamiphak, S. et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487–491 (2010).
Bae, J. H. et al. Gatekeeping role of Nf2/Merlin in vascular tip EC induction through suppression of VEGFR2 internalization. Sci. Adv. 8, eabn2611 (2022).
Genet, G. et al. Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis. Nat. Commun. 10, 2350 (2019).
Dumont, D. J. et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946–949 (1998).
Veikkola, T. et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, 1223–1231 (2001).
Leppanen, V. M. et al. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc. Natl Acad. Sci. USA 110, 12960–12965 (2013).
Makinen, T. et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7, 199–205 (2001).
He, Y. et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl Cancer Inst. 94, 819–825 (2002).
Matsumura, K. et al. Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3. Blood 101, 1367–1374 (2003).
Soker, S., Fidder, H., Neufeld, G. & Klagsbrun, M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem. 271, 5761–5767 (1996).
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735–745 (1998).
Pellet-Many, C., Frankel, P., Jia, H. & Zachary, I. Neuropilins: structure, function and role in disease. Biochem. J. 411, 211–226 (2008).
Vander Kooi, C. W. et al. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl Acad. Sci. USA 104, 6152–6157 (2007).
Sarabipour, S. & Mac Gabhann, F. VEGF-A121a binding to Neuropilins — a concept revisited. Cell Adh. Migr. 12, 204–214 (2018).
Lampropoulou, A. & Ruhrberg, C. Neuropilin regulation of angiogenesis. Biochem. Soc. Trans. 42, 1623–1628 (2014).
Xu, Y. et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol. 188, 115–130 (2010).
Teran, M. & Nugent, M. A. Characterization of receptor binding kinetics for vascular endothelial growth factor-A using SPR. Anal. Biochem. 564-565, 21–31 (2019).
Fantin, A. et al. Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development 141, 556–562 (2014).
Ema, M. & Rossant, J. Cell fate decisions in early blood vessel formation. Trends Cardiovasc. Med. 13, 254–259 (2003).
Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21, 193–215 (2011).
Geevarghese, A. & Herman, I. M. Pericyte-endothelial crosstalk: implications and opportunities for advanced cellular therapies. Transl. Res. 163, 296–306 (2014).
Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685–693 (2003).
Wang, H. U., Chen, Z. F. & Anderson, D. J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741–753 (1998).
Gale, N. W. et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl Acad. Sci. USA 101, 15949–15954 (2004).
Pitulescu, M. E. et al. Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. Nat. Cell Biol. 19, 915–927 (2017).
Swift, M. R. & Weinstein, B. M. Arterial-venous specification during development. Circ. Res. 104, 576–588 (2009).
Kearney, J. B., Kappas, N. C., Ellerstrom, C., DiPaola, F. W. & Bautch, V. L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 103, 4527–4535 (2004).
Chappell, J. C., Taylor, S. M., Ferrara, N. & Bautch, V. L. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev. Cell 17, 377–386 (2009).
Eilken, H. M. et al. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1. Nat. Commun. 8, 1574 (2017).
Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163–1177 (2003).
Geudens, I. & Gerhardt, H. Coordinating cell behaviour during blood vessel formation. Development 138, 4569–4583 (2011).
Yan, M. & Plowman, G. D. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 13, 7243–7246 (2007).
Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298–307 (2011).
Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691–703 (2007).
Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4, 336–340 (1998).
Kim, M. et al. VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. EMBO Mol. Med. 5, 1415–1430 (2013).
Liu, S. et al. Efficacy of anti-VEGF/VEGFR agents on animal models of endometriosis: a systematic review and meta-analysis. PLoS ONE 11, e0166658 (2016).
LeCouter, J. et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412, 877–884 (2001).
Ferrara, N. et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am. J. Pathol. 162, 1881–1893 (2003).
Roberts, J. M. & Cooper, D. W. Pathogenesis and genetics of pre-eclampsia. Lancet 357, 53–56 (2001).
Zeisler, H. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374, 13–22 (2016).
Thadhani, R. et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27, 903–913 (2016).
Makris, A. et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension 67, 1263–1272 (2016).
Turanov, A. A. et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36, 1164–1173 (2018).
Owen-Woods, C. & Kusumbe, A. Fundamentals of bone vasculature: specialization, interactions and functions. Semin. Cell Dev. Biol. 123, 36–47 (2022).
Gerber, H. P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5, 623–628 (1999).
Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323–328 (2014).
Sivaraj, K. K. & Adams, R. H. Blood vessel formation and function in bone. Development 143, 2706–2715 (2016).
Maes, C. et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech. Dev. 111, 61–73 (2002).
Street, J. et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl Acad. Sci. USA 99, 9656–9661 (2002).
Janowska-Wieczorek, A., Majka, M., Ratajczak, J. & Ratajczak, M. Z. Autocrine/paracrine mechanisms in human hematopoiesis. Stem Cell 19, 99–107 (2001).
Kabrun, N. et al. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 124, 2039–2048 (1997).
Gerber, H.-P. et al. VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954–958 (2002).
Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat. Med. 8, 841–849 (2002).
Gerber, H. P. & Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. 81, 20–31 (2003).
Gabrilovich, D. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150–4166 (1998).
de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).
Chung, A. S. et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19, 1114–1123 (2013).
Itatani, Y. et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc. Natl Acad. Sci. USA 117, 21598–21608 (2020).
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
Amersfoort, J., Eelen, G. & Carmeliet, P. Immunomodulation by endothelial cells — partnering up with the immune system? Nat. Rev. Immunol. 22, 576–588 (2022).
Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102–111 (2005).
Boucher, Y., Leunig, M. & Jain, R. K. Tumor angiogenesis and interstitial hypertension. Cancer Res. 56, 4264–4266 (1996).
Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911–920 (2007).
Liang, W. & Ferrara, N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol. Res. 4, 83–91 (2016).
Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825–831 (2007).
Negri, L. & Ferrara, N. The prokineticins: neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis. Physiol. Rev. 98, 1055–1082 (2018).
Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017).
Goswami, S., Anandhan, S., Raychaudhuri, D. & Sharma, P. Myeloid cell-targeted therapies for solid tumours. Nat. Rev. Immunol. 23, 106–120 (2023).
Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).
Crawford, Y. et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21–34 (2009).
Zhang, Y., Wang, S. & Dudley, A. C. Models and molecular mechanisms of blood vessel co-option by cancer cells. Angiogenesis 23, 17–25 (2020).
Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3, 411–421 (2003).
Uemura, A. et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog. Retin. Eye Res. 84, 100954 (2021).
Gariano, R. F. & Gardner, T. W. Retinal angiogenesis in development and disease. Nature 438, 960–966 (2005).
Ramshekar, A. & Hartnett, M. E. Vascular endothelial growth factor signaling in models of oxygen-induced retinopathy: insights into mechanisms of pathology in retinopathy of prematurity. Front. Pediatr. 9, 796143 (2021).
Hellstrom, A., Smith, L. E. & Dammann, O. Retinopathy of prematurity. Lancet 382, 1445–1457 (2013).
Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480–1487 (1994).
Adamis, A. P. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445–450 (1994).
Marneros, A. G. et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 167, 1451–1459 (2005).
Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A. E. & D’Amore, P. A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl Acad. Sci. USA 106, 18751–18756 (2009).
Zhang, Y. et al. Vascular endothelial growth factor from retinal pigment epithelium is essential in choriocapillaris and axial length maintenance. PNAS Nexus 1, pgac166 (2022).
Lejoyeux, R. et al. Choriocapillaris: fundamentals and advancements. Prog. Retin. Eye Res. 87, 100997 (2022).
Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med. 16, 1107–1111 (2010).
Jager, R. D., Mieler, W. F. & Miller, J. W. Age-related macular degeneration. N. Engl. J. Med. 358, 2606–2617 (2008).
Toto, L., Di Antonio, L., Costantino, O. & Mastropasqua, R. Anti-VEGF therapy in myopic CNV. Curr. Drug Targets 22, 1054–1063 (2021).
Heier, J. S. et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399, 729–740 (2022).
Claesson-Welsh, L. Vascular permeability — the essentials. Ups. J. Med. Sci. 120, 135–143 (2015).
Wautier, J. L. & Wautier, M. P. Vascular permeability in diseases. Int. J. Mol. Sci. 23, 3645 (2022).
Nagy, J. A., Chang, S. H., Dvorak, A. M. & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100, 865–869 (2009).
Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983).
Dvorak, H. F. Tumors: wounds that do not heal-A historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting. Semin. Thromb. Hemost. 45, 576–592 (2019).
Eliceiri, B. P. et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915–924 (1999).
Li, X. et al. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat. Commun. 7, 11017 (2016).
Sun, Z. et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J. Exp. Med. 209, 1363–1377 (2012).
Weis, S., Cui, J., Barnes, L. & Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 167, 223–229 (2004).
Chen, X. L. et al. VEGF-induced vascular permeability is mediated by FAK. Dev. Cell 22, 146–157 (2012).
Smith, R. O. et al. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. eLife 9, e54056 (2020).
Ethell, I. M. & Yamaguchi, Y. Cell surface heparan sulfate proteoglycan syndecan-2 induces the maturation of dendritic spines in rat hippocampal neurons. J. Cell Biol. 144, 575–586 (1999).
Termini, C. M. et al. Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity. Blood 139, 188–204 (2022).
Chen, E., Hermanson, S. & Ekker, S. C. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood 103, 1710–1719 (2004).
Corti, F. et al. Syndecan-2 selectively regulates VEGF-induced vascular permeability. Nat. Cardiovasc. Res. 1, 518–528 (2022).
van Bruggen, N. et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613–1620 (1999).
Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393–11398 (2002).
Campa, C. et al. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest. Ophthalmol. Vis. Sci. 49, 1178–1183 (2008).
Kwak, N., Okamoto, N., Wood, J. M. & Campochiaro, P. A. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41, 3158–3164 (2000).
Aiello, L. P. et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46, 1473–1480 (1997).
Nagy, J. A. et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab. Invest. 86, 767–780 (2006).
Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996).
Mao, A. S. & Mooney, D. J. Regenerative medicine: current therapies and future directions. Proc. Natl Acad. Sci. USA 112, 14452–14459 (2015).
Ferrara, N. & Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359–1364 (1999).
Bao, P. et al. The role of vascular endothelial growth factor in wound healing. J. Surg. Res. 153, 347–358 (2009).
Lopez, J. J. et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc. Res. 40, 272–281 (1998).
Pearlman, J. D. et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat. Med. 1, 1085–1089 (1995).
Henry, T. D. et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107, 1359–1365 (2003).
Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967–974 (2005).
L’Heureux, N., McAllister, T. N. & de la Fuente, L. M. Tissue-engineered blood vessel for adult arterial revascularization. N. Engl. J. Med. 357, 1451–1453 (2007).
Anderson, S. M., Siegman, S. N. & Segura, T. The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching. Biomaterials 32, 7432–7443 (2011).
Hou, L., Kim, J. J., Woo, Y. J. & Huang, N. F. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 310, H455–H465 (2016).
Leeper, N. J., Hunter, A. L. & Cooke, J. P. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells. Circulation 122, 517–526 (2010).
Ron, D. & Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529 (2007).
Costa-Mattioli, M. & Walter, P. The integrated stress response: from mechanism to disease. Science 368, eaat5314 (2020).
Zhang, K. et al. The unfolded protein response sensor IRE1α is required at 2 distinct steps in B cell lymphopoiesis. J. Clin. Invest. 115, 268–281 (2005).
Iwawaki, T., Akai, R., Yamanaka, S. & Kohno, K. Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability. Proc. Natl Acad. Sci. USA 106, 16657–16662 (2009).
Karali, E. et al. VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. Mol. Cell 54, 559–572 (2014).
Loinard, C. et al. C/EBP homologous protein-10 (CHOP-10) limits postnatal neovascularization through control of endothelial nitric oxide synthase gene expression. Circulation 125, 1014–1026 (2012).
Zhong, C. et al. Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways. Nat. Commun. 11, 6330 (2020).
Fels, D. R. & Koumenis, C. The PERK/eIF2α/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol. Ther. 5, 723–728 (2006).
Liu, L. et al. Targeting the IRE1α/XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. Am. J. Pathol. 182, 1412–1424 (2013).
Rivard, A. et al. Age-dependent impairment of angiogenesis. Circulation 99, 111–120 (1999).
Jia, G., Aroor, A. R., Jia, C. & Sowers, J. R. Endothelial cell senescence in aging-related vascular dysfunction. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1802–1809 (2019).
Hayashi, T. et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc. Natl Acad. Sci. USA 103, 17018–17023 (2006).
Yang, Y. M., Huang, A., Kaley, G. & Sun, D. eNOS uncoupling and endothelial dysfunction in aged vessels. Am. J. Physiol. Heart Circ. Physiol. 297, H1829–H1836 (2009).
Cheng, X. W. et al. Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase/Akt-dependent hypoxia-induced factor-1α reactivation in mice of advanced age. Circulation 122, 707–716 (2010).
Grunewald, M. et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science 373, abc8579 (2021).
Augustin, H. G. & Kipnis, J. Vascular rejuvenation is geroprotective. Science 373, 490–491 (2021).
Marneros, A. G. Effects of chronically increased VEGF-A on the aging heart. FASEB J. 32, 1550–1565 (2018).
Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149–1159 (1999).
Murakami, M. et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118, 3355–3366 (2008).
Oladipupo, S. S. et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc. Natl Acad. Sci. USA 111, 13379–13384 (2014).
Li, P. & Ferrara, N. Vascular heterogeneity: VEGF receptors make blood vessels special. J. Exp. Med. 219, e20212539 (2022).
Karaman, S. et al. Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance. J. Exp. Med. 219, e20210565 (2022).
Bosco, J. et al. VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 21, 369–381 (2021).
Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310–324 (2018).
Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151–172 (2022).
Rafii, S., Butler, J. M. & Ding, B. S. Angiocrine functions of organ-specific endothelial cells. Nature 529, 316–325 (2016).
Perez-Gutierrez, L., Li, P. & Ferrara, N. Endothelial cell diversity: the many facets of the crystal. FEBS J. https://doi.org/10.1111/febs.16660 (2022).
Li, P. et al. LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy. EMBO Mol. Med. 14, e14511 (2022).
Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385–403 (2016).
Kim, K. J., Li, B., Houck, K., Winer, J. & Ferrara, N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53–64 (1992).
Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841–844 (1993).
Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463–475 (2007).
Bais, C. et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141, 166–177 (2010).
Fala, L. Cyramza (ramucirumab) approved for the treatment of advanced gastric cancer and metastatic non-small-cell lung cancer. Am. Health Drug Benefits 8, 49–53 (2015).
Lu, D. et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem. 278, 43496–43507 (2003).
Kumar, R. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717–1723 (2009).
Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248–1264 (2019).
Makker, V. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. 386, 437–448 (2022).
Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802–805 (2021).
Courtney, K. D. et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res. 26, 793–803 (2020).
Ferrara, N. VEGF and intraocular neovascularization: from discovery to therapy. Transl. Vis. Sci. Technol. 5, 10 (2016).
Ferrara, N., Damico, L., Shams, N., Lowman, H. & Kim, R. Developmemt of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859–870 (2006).
Vorum, H., Olesen, T. K., Zinck, J. & Hedegaard, M. Real world evidence of use of anti-VEGF therapy in Denmark. Curr. Med. Res. Opin. 32, 1943–1950 (2016).
Saint-Geniez, M. et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE 3, e3554 (2008).
Long, D. et al. VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight 3, e120231 (2018).
Xin, H. et al. Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders. Proc. Natl Acad. Sci. USA 118, e1921252118 (2021).
Karle, A. C. et al. Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events. Sci. Transl Med. 15, eabq5241 (2023).
Sydnor, S. et al. Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and network meta-analysis. Diabetes Ther. 14, 1193–1216 (2023).
Jackson, T. L. et al. A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration. Ophthalmology 130, 588–597 (2023).
Acknowledgements
This work is supported by the National Institute of Health, award number R01EY031345. L.P.-G. is additionally supported by funding from an EMBO Postdoctoral Fellowship under grant agreement no. ALTF 126–2022.
Author information
Authors and Affiliations
Contributions
Both authors wrote the article and critically discussed the contents.
Corresponding author
Ethics declarations
Competing interests
N.F. is a co-founder of Theia Therapeutics and NVasc. L.P.-G. declares no competing interests.
Peer review
Peer review information
Nature Reviews Molecular Cell Biology thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Pérez-Gutiérrez, L., Ferrara, N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol 24, 816–834 (2023). https://doi.org/10.1038/s41580-023-00631-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41580-023-00631-w
This article is cited by
-
Liquid plasma promotes angiogenesis through upregulation of endothelial nitric oxide synthase-induced extracellular matrix metabolism: potential applications of liquid plasma for vascular injuries
Cell Communication and Signaling (2024)
-
CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance
Cellular Oncology (2024)
-
Report from the 2023 workshop on endothelial permeability, edema and inflammation
Nature Cardiovascular Research (2023)
